Sagar Lonial, MD, FACP



Dr. Lonial's research focus is with combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway.

Titles and Roles

Chief Medical Officer
Winship Cancer Institute of Emory University
Professor and Chair, Department of Hematology and Medical Oncology
Emory University School of Medicine
Anne and Bernard Gray Family Chair in Cancer
Emory University School of Medicine
Multiple Myeloma
Bone Marrow and Stem Cell Transplant Center
Phase I Clinical Trials Unit
Research Program
Discovery and Developmental Therapeutics


Sagar Lonial, MD, FACP, is internationally recognized as a leading authority in multiple myeloma treatment and research. As a medical oncologist at the Winship Cancer Institute, Dr. Lonial treats patients with multiple myeloma and is a lead member of the bone marrow transplantation team and clinical trials team. He is board certified in hematology and medical oncology.

Dr. Lonial is involved in numerous professional organizations including American Society of Clinical Oncology, American Society of Hematology, and American Society for Blood and Marrow Transplantation. He serves Vice Chair of the Finance Committee of the International Myeloma Society, and serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group. He also serves as President and Chair of the Society of Hematologic Oncology. Additionally, he is on the Scientific Advisory Board for the International Myeloma Foundation.


Dr. Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology and oncology at Emory University School of Medicine in Atlanta, Georgia.


Dr. Lonial has worked in the field of immunotherapy and cancer since his arrival at Emory, and in the previous 3 years has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen, and he has completed several trials evaluating the impact of cytokines on dendritic cell content and post transplant immune recovery.

Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway. His lab has recently received funding from the MMRF, the Lymphoma Research Foundation, and The Leukemia & Lymphoma Society.

  • Below is a listing of current federal grants for the above principal investigator.



Dr. Lonial has authored or coauthored over 200 peer-reviewed publications. He serves on the editorial board of the Journal of Clinical Oncology, Leukemia, is the myeloma editor for Clinical Lymphoma, Myeloma, and Leukemia, and is the hematologic malignancies section editor for the journal Cancer. In addition, he is an invited or ad hoc reviewer for several publications, including Blood, and Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others.

  • PublicationsPublication Date


Dr. Lonial is a recipient of the following awards:

  • Giants of Cancer Care, Myeloma Award Category, OncLive, 2020
  • MilliPub Club Award, Emory University School of Medicine, 2015, 2020, 2022
  • Lifetime Achievement Award for Outstanding Contributions to Hematology-Oncology, Indo-American Cancer Association, 2017
  • Celgene 'Young Investigator' Award
  • MMRF 'Top 15 Innovator' Award
  • MMRC 'Center of the Year' award
  • Multiple Myeloma Research Foundation
  • Henry B. Macintosh Award, 1996
  • Houston Society of Internal Medicine, Best Resident in Internal Medicine, 1995

Additional Websites

Cascade Link   TOP